Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8221 results

  1. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development

  3. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    Awaiting development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

    In development Reference number: GID-MT526 Expected publication date: TBC

    Medical technologies guidance
    In development

  5. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development Reference number: GID-TA11373 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Domestic Abuse: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 27 January 2026.

    NICE guideline
    In consultation

  7. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  9. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  10. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  11. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI

    In development Reference number: GID-IPG10439 Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  14. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    In development Reference number: GID-TA11440 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development